

Fig. 1A




Fig. 1B




Fig. 1C




Fig. 2A

Human CD4 T cells from hu-PBL-SCID-spl
Immunized with





Fig. 2B



Lymphocytes from hu-PBL-SCID mice
immunized with:

Fig. 3




Fig. 4





Fig. 5

HIV-1 copies/10000 actin copies



HIV-1 standard





Fig. 6A

% inhibition of R5 HIV-1



% inhibition of X4 HIV-1




Fig. 6B




Fig. 7A




Fig. 7B




Fig. 7C




Fig. 8 CCR5 expression




Fig. 9

TABLE 1 Protection of hu-PBL-SCID-spl mice against HIV-1 infection by immunization with HIV-1-pulsed DC.

hu-PBL-SCID-spl mice immunized with	n	#provirus ¹ ($\times 10^{-3}$)	culture p24 ² (ng/ml)	serum human chemokine (ng/ml) ³	
				MIP-1 α	MIP-1 β RANTES
Donor 1	OVA	8	10.9 \pm 5.2	60.3 \pm 23.9	nd
	HIV-1 _{JR-CSF}	4	<10	<0.2	nd
	HIV-1NL4-3	4	<10	<0.2	nd
Donor 2	OVA	4	7.8 \pm 4.1	9.5 \pm 7.6	1.65 \pm 0.47
	HIV-1 _{JR-CSF}	4	<10	<0.2	1.16 \pm 0.08
	HIV-1NL4-3	4	<10	<0.2	0.62 \pm 0.10

The hu-PBL-SCID-spl mice immunized with either DC-OVA or DC-AT-2-inactivated HIV-1 particles were infected with HIV-1_{JR-CSF}. After 7 days, serum and lymphocyte samples recovered from spleen and peritoneal cavity of hu-PBL-SCID-spl mice were examined for HIV-1 infection and serum chemokine levels.

¹HIV-1 provirus copy number of the fresh samples per total recovered cells from individual mouse.

²HIV-1 p24 concentration in the supernatants of the lymphocytes cultured at 1×10^6 cells/ml for 5 days.

³Human chemokine concentrations in the serum samples as determined by ELISA.